Pain Management News and Research

RSS

Simple pain relievers a better alternative to antipsychotic medications for dementia patients

Many dementia patients are being treated with antipsychotic medications, but a new study shows that simple pain relievers may be a better alternative.

8 Sep 2011

Experts to address crucial issues of pain management and disability health reform

Leading Australian and international medical experts will convene in Brisbane next week to address crucial areas of rehabilitation medicine, including health reform, barriers to rehabilitation healthcare services and pain management.

7 Sep 2011

Oxycodone no safer than codeine for breastfed infants: New study

Doctors have been prescribing codeine for postpartum pain management for many years, and, until recently, it was considered safe to breastfeed while taking the opioid. But the death of an infant exposed to codeine through breast milk has many health care providers questioning the safety of the drug when used by breastfeeding mothers.

7 Sep 2011

ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has entered into agreements with Quintiles Commercial US, Inc. and Integrated Commercialization Services, Inc. (ICS) to support the anticipated launch of EXPAREL, should it be approved by the Food and Drug Administration (FDA) later this year.

6 Sep 2011

Physio-Control announces commercial availability of ReadyLink 12-Lead ECG device

Physio-Control, Inc., a global leader in emergency medical solutions and wholly‐owned subsidiary of Medtronic, Inc.,, today announced commercial availability of the ReadyLink™ 12-Lead ECG device, a new, U.S. Food and Drug Administration (FDA) 510(k)-cleared solution designed to improve care for heart attack patients and expand regional STEMI systems.

From Medtronic 24 Aug 2011

Masimo SEDLine brain function monitor receives CE Mark

Masimo announced today that it has received CE Mark for its SEDLine brain function monitor — expanding access to and availability of SEDLine's advanced neuromonitoring technology to hospitals and clinicians across Europe. The

24 Aug 2011

Smokers more likely to report problems with persistent musculoskeletal pain

Smokers are much more likely to report problems with persistent musculoskeletal pain than non-smokers, according to a new study reported in the Journal of Pain, published by the American Pain Society.

24 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Dissimilar interaction of opioid receptors may explain why men, women experience pain differently

Women and men experience pain, particularly chronic pain, very differently. The ability of some opioids to relieve pain also differs between women and men. While it has been recognized since the mid-nineties that some narcotic analgesics are more effective in women than men, the reason for this difference was largely unknown.

19 Aug 2011

Endo terminates collaboration and axomadol development program with Grunenthal

Endo Pharmaceuticals announced today that it is terminating its research program and collaboration related to the development of axomadol.

18 Aug 2011

DJOFL second quarter net sales increase 14.5% to $277.8 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the second quarter of fiscal 2011, ended July 2, 2011.

16 Aug 2011

Pain care management needs to be improved: CMAJ

Pain care management needs to be improved, with health care professionals committing to improve care as well as a retooling of the health care system to help people who are suffering, states an editorial in CMAJ.

16 Aug 2011

Medical Facilities second quarter revenue increases to $54.3 million

Medical Facilities Corporation, today reported its financial results for the three-month and six-month periods ended June 30, 2011.

12 Aug 2011

Pacira second quarter total revenues increase to $3.6 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and updated its 2011 financial guidance.

11 Aug 2011

Boston Scientific introduces NLI online resource center for healthcare providers

Boston Scientific Corporation has launched its Neuromodulation Learning Institute (NLI), a clinical education program and online resource center for healthcare providers to enhance their knowledge and awareness of spinal cord stimulation (SCS) technology, procedures and techniques.

11 Aug 2011

OCM medical director receives AANEM's accreditation for electrodiagnostic lab in NJ

One Call Medical (OCM), the nation's leading provider of specialty services to insurance payers, today announced that its medical director, Dr. John Robinton, received recognition by the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) as having the first accredited electrodiagnostic laboratory in the state of New Jersey—and the additional distinction of "Accreditation with Exemplary Status."

9 Aug 2011

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

AstraZeneca today announced that study centers across the U.S. are recruiting patients for a clinical study to examine whether an investigational drug is safe and effective in treating opioid-induced constipation.

2 Aug 2011

FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules

Lannett Company, Inc. today announced the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for Phentermine Resin Extended-Release Capsules, 15 mg and 30 mg, representing the fourth product approval the company has received in the last five weeks.

29 Jul 2011

Cadence confirms FDA dosing recommendations for OFIRMEV

Cadence Pharmaceuticals, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.